
“I had treatment last year and I want to give something back.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is looking at how zoledronic acid works in women with early breast cancer. And why it seems to only help women who have been through the menopause.
Bisphosphonates are drugs that make bones stronger. Some women have them as part of their breast cancer treatment to prevent bone damage. You might have a type of bisphosphonate drug called zoledronic acid.
Early research shows that if a woman has zoledronic acid then her cancer is less likely to come back or spread to the bones. But this benefit is only seen in women who have been through the menopause. And not in women who haven’t.
Researchers don’t know exactly why this is. They think it has something to do with changing hormone levels that happen after the menopause. But they don’t know for sure. So, they want to find out more.
In this study, they are looking at the changes that zoledronic acid causes in blood and cancer cells. They hope this information will help to predict who will benefit most from zoledronic acid.
The aim of this study is to find out how and why zoledronic acid works in women with breast cancer.
Please note, taking part in this study might not benefit you directly. But it might help people with early breast cancer in the future.
You’ll see a doctor and have some blood tests before you join the study.
You have 3 to 4 extra visits if you join this study. Where possible you have them on the day of your routine visits.
At each visit, you’ll have a check up and blood tests.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Janet Brown
Yorkshire Cancer Research
Weston Park Cancer Charity
University of Sheffield
Sheffield Teaching Hospitals NHS Foundation Trust
Freephone 0808 800 4040
“I had treatment last year and I want to give something back.”